JTJaya R. Trivedi

Jaya R. Trivedi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jaya R. Trivedi has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Strategies for Improving Access in Academic Neurology

    by Jaya Trivedi, Amber Salter, Debra Clamp, Alan Kramer, Chelsea Landon

    Neurologic disorders, now a leading cause of disease burden globally, have further added to the growing concerns of access to care, especially given the anticipated 19% shortfall of neurologists. There is a pressing need to improve access and decrease appointment wait times. We led a departmental initiative to bridge the access gap. We focused on template management, leveraging advanced practice providers (APPs), and provision of timely access for new patients. Over 2 years, the total patient volume and the new patient volume increased by 34% and 32%, respectively. Visits per clinic session grew by 21% for APPs. The number of new patients seen within 10 days grew from 19% to 42% (123% increase) for internal referrals and from 21% to 43% (100% increase) for all referrals. This article reviews our strategies in improving patient access.


  • Open Access

    Database Evaluation for Muscle and Nerve Diseases - DEMAND: An academic neuromuscular coding system

    by Mamatha Pasnoor, Saud Khan, Carlayne E. Jackson, John Kissel, Gil I. Wolfe, Sharon P. Nations, Jaya R. Trivedi, Mike A. Singer, Jeffrey L. Elliott, Steven Vernino, et al.

    Background: A database which documents the diagnosis of neuromuscular patients is useful for determining the types of patients referred to academic centers and for identifying participants for clinical trials and other studies. The ICD-9 or ICD-10 numeric systems are insufficiently detailed for this purpose. Objective: To develop a database for neuromuscular diagnoses Methods: We developed a detailed diagnostic coding system for neuromuscular diseases called DEMAND: Database Evaluation for Muscle and Nerve Diseases that has been adopted by neuromuscular clinics at University of Texas Health Science Center San Antonio (UTHSCSA), Ohio State University (OSU), University of Kansas Medical Center (KUMC), and University of Texas Southwestern (UTSW). At the initial visit, patients are assigned a diagnostic code which can be revised later if appropriate. Fields include patient’s name, date of birth, and diagnostic code. The neuromuscular database consisted of 457 codes. Each code has a prefix (MUS or PNS) followed by a three-digit number. Depending on whether muscle or nerve is primarily involved, there are eight broad groups: motor neuron disease (MUS codes 100-139); neuromuscular junction disorders (MUS 200-217); acquired and hereditary myopathies (MUS 300-600s); acquired and hereditary polyneuropathies (PNS 100-400); mononeuropathies (PNS 500s); plexopathies (PNS 600s); radiculopathies (PNS 700s); and mononeuritis multiplex (PNS 800s). Results: During a period of 10 years, 17,163 of patients were entered (1,752 at UTHSCSA, 1,840 at OSU, 3,699 at KUMC, 9,872 at UTSW). The number of patients in several broad categories are: 3,080 motor neuron disease; 1,575 neuromuscular junction disease; 1,851 muscular dystrophies; 633 inflammatory myopathies; 1,090 hereditary neuropathies; 1,001 immune-mediated polyneuropathies; 620 metabolic/toxic polyneuropathies; 535 mononeuropathies; 296 plexopathies; and 769 radiculopathies. Conclusion: A detailed diagnostic neuromuscular database can be utilized at multiple academic centers. The database should be simple without too many fields to complete, to ensure compliance during busy clinic operations. This database has been very useful in identifying groups of patients for retrospective, observational studies and for prospective treatment studies including trials for Amyotrophic Lateral Sclerosis (ALS), Muscular Dystrophies (MD), Myasthenia Gravis (MG), and retrospective studies of Primary Lateral Sclerosis (PLS), chronic inflammatory demyelinating neuropathy (CIDP), etc.


  • Muscle Channelopathies

    by Jaya R. Trivedi

    Etic testing is needed to make a definitive diagnosis. Electrodiagnostic testing in channelopathies is highly specialized with significant overlap in various mutation subtypes. Randomized clinical trials have now been conducted in these disorders with expanded treatment options for patients with muscle channelopathies. SUMMARY Skeletal muscle channelopathies are rare heterogeneous conditions characterized by lifelong symptoms that require a comprehensive management plan that includes pharmacologic and nonpharmacologic interventions. The significant variability in biophysical features of various mutations, coupled with the difficulties of performing clinical trials in rare diseases, makes it challenging to design and implement treatment trials for muscle channelopathies....


  • Open Access

    Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices

    by Marie Wencel, Aziz Shaibani, Namita A. Goyal, Mazen M. Dimachkie, Jaya Trivedi, Nicholas E. Johnson, Laurie Gutmann, Matthew P. Wicklund, Sankar Bandyopadhay, Angela L. Genge, et al.

    Background and Objectives We investigated the prevalence of late-onset Pompe disease (LOPD) in patients presenting to 13 academic, tertiary neuromuscular practices in the United States and Canada. Methods All successive patients presenting with proximal muscle weakness or isolated hyperCKemia and/or neck muscle weakness to these 13 centers were invited to participate in the study. Whole blood was tested for acid alpha-glucosidase (GAA) assay through the fluorometric method, and all cases with enzyme levels of ≤10 pmoL/punch/h were reflexed to molecular testing for mutations in the GAA gene. Clinical and demographic information was abstracted from their clinical visit and, along with study data, entered into a purpose-built REDCap database, and analyzed at the University of California, Irvine. Results GAA enzyme assay results were available on 906 of the 921 participants who consented for the study. LOPD was confirmed in 9 participants (1% prevalence). Another 9 (1%) were determined to have pseudodeficiency of GAA, whereas 19 (1.9%) were found to be heterozygous for a pathogenic GAA mutation (carriers). Of the definite LOPD participants, 8 (89%) were Caucasian and were heterozygous for the common leaky (IVS1) splice site mutation in the GAA gene (c -32-13T>G), with a second mutation that was previously confirmed to be pathogenic. Discussion The prevalence of LOPD in undiagnosed patients meeting the criteria of proximal muscle weakness, high creatine kinase, and/or neck weakness in academic, tertiary neuromuscular practices in the United States and Canada is estimated to be 1%, with an equal prevalence rate of pseudodeficiency alleles. Trial Registration Information Clinical trial registration number: NCT02838368.


  • New patient access via telehealth in neuromuscular medicine during COVID-19

    by Shaida Khan, Alan Kramer, Johnathan McIver, Leah Cady, Jaya R. Trivedi

    BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has changed the face of health care delivery. Health care institutions rapidly transitioned to telehealth to provide care to patients. Prior to the pandemic, telehealth services extended mostly to patients with established diagnoses. Driven by a necessity to provide care to all patients during the pandemic, neurologists started evaluating new patients also via telehealth. OBJECTIVE: To explore opportunities, challenges, and feasibility of telehealth for new patients with neuromuscular disorders. METHODS: New patient visits performed in our neuromuscular clinic were analyzed from March 18, 2020 - July 31, 2020. Data collected included visit volume, demographics, geographic distance of patient’s residence from our institution, and no-show and cancellation rates. RESULTS: Total number of patients seen was 1,471; 472 (32%) were new patients. No-show and cancellation rates for telehealth visits were lower than historical in-person visits. There was a wide range of ages (35–74 years) with representation of new patients from a large geographical territory. CONCLUSION: This study advances our understanding regarding the adoption and implementation of telehealth for new patients. Our clinic was able to provide timely access and care to a significant number of patients who could not travel to our institution during COVID-19.


  • Guidelines on clinical presentation and management of nondystrophic myotonias

    by Bas C. Stunnenberg, Samantha LoRusso, W. David Arnold, Richard J. Barohn, Stephen C. Cannon, Bertrand Fontaine, Robert C. Griggs, Michael G. Hanna, Emma Matthews, Giovanni Meola, et al.

    The nondystrophic myotonias are rare muscle hyperexcitability disorders caused by gain‐of‐function mutations in the SCN4A gene or loss‐of‐function mutations in the CLCN1 gene. Clinically, they are characterized by myotonia, defined as delayed muscle relaxation after voluntary contraction, which leads to symptoms of muscle stiffness, pain, fatigue, and weakness. Diagnosis is based on history and examination findings, the presence of electrical myotonia on electromyography, and genetic confirmation. In the absence of genetic confirmation, the diagnosis is supported by detailed electrophysiological testing, exclusion of other related disorders, and analysis of a variant of uncertain significance if present. Symptomatic treatment with a sodium channel blocker, such as mexiletine, is usually the first step in management, as well as educating patients about potential anesthetic complications.


  • A 28-Year-Old Woman with Proximal Limb Weakness and Scapular Winging

    by Rahul Abhyankar, Chunyu Cai, Jaya R. Trivedi

  • Subcutaneous Immunoglobulin in Myasthenia Gravis: Results of a North American Open Label Study (N4.002)

    by Mazen Dimachkie, Vera Bril, Todd Levine, Jaya Trivedi, Nicholas Silvestri, Milind Phadnis, David Saperstein, Sharon Nations, Hans Katzberg, Gil Wolfe, et al.